Teva/Mylan Settle Glatiramer Litigation In UK, Netherlands, France

Teva Pharmaceutical Industries and Mylan have disclosed that certain of their affiliates have agreed to settle and dismiss pending patent litigation regarding a proposed generic version of Teva's Copaxone (glatiramer acetate) in the UK, the Netherlands and France. The litigation related to European Patent 0,762,888, which expires in May 2015. The terms of the settlement have not been disclosed.

Teva and Mylan have been battling over the patent for some time. In October, the District Court of the Hague, in the Netherlands, issued a ruling in favour of Teva; Mylan had brought a patent revocation action and had been seeking a court judgement that the '888 patent was invalid. However, the District Court rejected each one of the grounds of invalidity that Mylan had raised against the claims of the patent. The ruling in the Netherlands followed a similar ruling in Teva's favour in the English Court of Appeal in July, again in a case involving Mylan and that also affirmed that the claims of Teva's '888 patent are valid.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: Europe, France, United Kingdom, Israel, Netherlands, United States

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.